Breaking Finance News

A statement released earlier today by H.C. Wainwright about Bio-Path Holdings (NDAQ:BPTH) bumps down the target price to $1.50

H.C. Wainwright lowered the target price of Bio-Path Holdings (NDAQ:BPTH) to $1.50 reporting a potential upside of 4%.

Previously on Friday April 07, 2017, H.C. Wainwright reported on Bio-Path Holdings (NDAQ:BPTH) increased the target price from $0.00 to $5.00. At the time, this indicated a possible upside of 5.94%.

Just yesterday Bio-Path Holdings (NDAQ:BPTH) traded 0.00% even at $0.30. Bio-Path Holdings’s 50-day moving average is $0.39 and its 200-day moving average is $0.65. The last closing price is down -43.16% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.02% over the same time period. 172,927 shares of BPTH traded hands, down from an average trading volume of 623,200

Recent Performance Chart

Bio-Path Holdings (NDAQ:BPTH)

Bio-Path Holdings has 52 week low of $0.33 and a 52 week high of $1.75 and has a market capitalization of $0.

In addition to H.C. Wainwright reporting its stock price target, a total of 1 broker has issued a research note on the company. The average stock price target is $5.00 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Bio-Path Holdings (NDAQ:BPTH)

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.